Recurrent UTI generally means at least two episodes in six months or three in a year. Testing helps confirm the cause and guide prevention. Here are the options with supporting evidence, the limits of supplements and when you need ongoing care.
Recurrent UTI generally means at least two episodes in six months or three in a year. The AUA/CUA/SUFU guideline emphasizes documenting symptoms, inflammation and bacteria and obtaining urine testing for recurrent episodes. Repeated urinary symptoms are not always repeated infections; irritation and other bladder or pelvic conditions can overlap.
If you think you have recurrent UTIs, ask for a urine culture on your next symptomatic episode. Without culture data, the prevention plan is less targeted.
Hydration may help if you currently drink little. In a trial of premenopausal women with recurrent UTIs who drank less than 1.5 liters of fluid daily, adding 1.5 liters of water reduced episodes over a year. This does not mean everyone should force extra water. Follow any fluid restriction for heart, kidney or other conditions. Read the hydration trial.
Discuss a suitable fluid intake with your clinician if you have heart or kidney disease, take medicines that affect fluid balance, or have a prescribed fluid restriction.
One of the most effective interventions in this group. Vaginal estradiol or estriol — as a cream, tablet, or ring — restores vaginal and periurethral tissue health and shifts the microbiome back toward protective lactobacilli. The AUA guideline explicitly recommends it for recurrent UTI in peri- and postmenopausal women. Systemic absorption at vaginal doses is minimal, so it's considered safe even for many patients who avoid systemic hormone therapy.
Some patients with documented recurrent UTIs benefit from a clinician-prescribed preventive antibiotic or a specific self-start plan. Drug, dose, timing and duration depend on the patient and test history. A self-start plan is not permission to use leftover antibiotics. Discuss risks, follow-up and alternatives with the clinician managing recurrence.
All reduce UTI recurrence significantly in trials. Trade-offs: antibiotic resistance, C. diff risk over time, and side effects (nitrofurantoin has pulmonary and hepatic risks with long-term use and is avoided with reduced kidney function).
D-mannose: early studies were encouraging, but a larger 2024 placebo-controlled trial did not show a meaningful preventive benefit. Among 598 women assigned to 2 g daily or placebo for six months, medically attended suspected UTIs occurred in 51.0% versus 55.7%; the difference was not statistically significant. The 2025 AUA guideline advises that D-mannose alone may not be effective. It should not be presented as a proven first-line prevention step or used to delay treatment of current symptoms. 2024 randomized trial; 2025 AUA guideline.
Cranberry products can reduce recurrence for some people with recurrent UTIs. They do not treat an active infection. Studies used different preparations and doses, so no single capsule strength or juice serving is proven to work for everyone. Consider product quality, sugar content, cost and medication interactions with your clinician or pharmacist. Cochrane review.
Urinating after sex is reasonable if comfortable, but good evidence that it prevents recurrent UTIs is limited. It should not be presented as a proven prevention step or something a patient caused an infection by forgetting.
Methenamine hippurate is a non-antibiotic preventive option for some people with recurrent UTIs after any active infection has been treated. It requires prescribing review and is not treatment for a current UTI. Discuss whether it is appropriate alongside options such as vaginal estrogen around menopause. NICE prevention guidance.
Vaccines and bacterial immunotherapies such as sublingual MV140 are being studied for recurrent UTIs. Promising results do not establish a routine preventive option for every patient, and long-term uncontrolled follow-up cannot measure a reduction compared with placebo. This article does not recommend obtaining an unapproved product. MV140 randomized trial.
Behavioral and non-antibiotic measures are long-term. Prophylactic antibiotics are typically 3–12 months, with reassessment. About 50% of patients who discontinue prophylaxis recur within 3–6 months, so some patients stay on longer.
Only if your provider has explicitly set up a patient-initiated self-start regimen with you and you have an active prescription for that purpose. Using random leftover antibiotics breeds resistance and masks the actual organism.
A reliable benefit for preventing recurrent UTIs has not been established for routine probiotic use. Products differ, and suitability depends on the individual; they do not replace evaluation of repeated symptoms.
If episodes follow sex, discuss avoiding spermicides and whether clinician-prescribed prevention is appropriate. Evidence for urinating after sex is limited, and D-mannose has not shown reliable preventive benefit.
Not automatically. Uncomplicated recurrent cystitis can often be managed in primary care or via telehealth. See urology if you have red flags: blood between infections, flank pain, male sex, prior complicated UTI, or failure of first-line prevention.